PepGen 3Q 2026: EPS ($0.28) — 10-Q Summary
PepGen reported no revenue and a net loss of $19.39M for 3Q 2026, with higher R&D and clinical trial costs. EPS improved to ($0.28) from ($0.52) YoY. FREEDOM2 trial showed 46.5% splicing correction at 10 mg/kg, but remains on partial clinical hold. PepGen enrolled 19 participants in FREEDOM-OLE and discontinued DMD-related R&D.
How this was made
The 30-second read
Why it matters
The disclosed loss and continued trial holds keep the stock under pressure, but the reported splicing correction rates may attract speculative interest.
Market read
Quarterly loss and trial updates are primary news for PepGen shareholders and biotech traders.
What to watch
Potential future FDA engagement and upcoming data from the 12.5 mg/kg cohort could change the narrative.
Background
PepGen is a micro‑cap biotech focused on RNA‑splicing therapies. The 10‑Q reports ongoing preclinical and early‑stage clinical work with no commercial revenue.
Ticker impact
PepGen disclosed Q3 2026 net loss widening to $19.39M and EPS of -$0.28 in its 10‑Q filing.
downward pressure as investors price in higher expenses and no revenue
Quarterly results show a larger loss than the prior year and no revenue, which typically triggers sell‑offs in micro‑cap biotech.
Market effects
Highlights ongoing challenges for early‑stage gene‑therapy firms and may dampen sentiment in the rare‑disease biotech niche.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If the trial data for FREEDOM2 shows strong splicing correction, some investors may view the loss as a short‑term pain for long‑term upside.
Key entities
- companyPepGen Inc.
Biotech company developing RNA‑splicing therapies.
